Diverse microtubule-targeted anticancer agents kill cells by inducing chromosome missegregation on multipolar spindles
暂无分享,去创建一个
M. Burkard | Beth A. Weaver | John B. Tucker | Christina M. Scribano | Andrew R Lynch | Amber S Zhou | Amber S. Zhou | Caleb L. Carlsen | Sophia T. Pop-Vicas | Srishrika M. Pattaswamy | Caleb L Carlsen | Srishrika M Pattaswamy
[1] Z. Storchová,et al. Consequences of chromosome gain: A new view on trisomy syndromes. , 2022, American journal of human genetics.
[2] G. Kops,et al. Nuclear chromosome locations dictate segregation error frequencies , 2022, Nature.
[3] B. Weaver,et al. Chromosome Missegregation as a Modulator of Radiation Sensitivity. , 2022, Seminars in radiation oncology.
[4] M. Burkard,et al. Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel , 2021, Science Translational Medicine.
[5] T. Ried,et al. Clonal selection of stable aneuploidies in progenitor cells drives high-prevalence tumorigenesis , 2021, Genes & development.
[6] P. Meraldi,et al. Forcing dividing cancer cells to die; low‐dose drug combinations to prevent spindle pole clustering , 2021, Apoptosis.
[7] J. Korbel,et al. Systems approaches identify the consequences of monosomy in somatic human cells , 2021, Nature Communications.
[8] A. Roopra,et al. p53 Is Not Required for High CIN to Induce Tumor Suppression , 2020, Molecular Cancer Research.
[9] Karen H. Miga,et al. Human chromosome‐specific aneuploidy is influenced by DNA‐dependent centromeric features , 2019, The EMBO journal.
[10] A. Amon,et al. Context is everything: aneuploidy in cancer , 2019, Nature Reviews Genetics.
[11] H. Funabiki,et al. The Cytoplasmic DNA Sensor cGAS Promotes Mitotic Cell Death , 2019, Cell.
[12] Christopher D. Laucius,et al. Chromosomal instability suppresses the growth of K-Ras-induced lung adenomas , 2019, Cell cycle.
[13] S. McClelland,et al. Impaired CENP-E Function Renders Large Chromosomes More Vulnerable to Congression Failure , 2019, Biomolecules.
[14] Z. Storchová,et al. The diverse consequences of aneuploidy , 2019, Nature Cell Biology.
[15] I. Huijbers,et al. Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division , 2018, British Journal of Cancer.
[16] F. Foijer,et al. Non-random Mis-segregation of Human Chromosomes , 2018, bioRxiv.
[17] D. Grieco,et al. Fighting tubulin-targeting anticancer drug toxicity and resistance. , 2017, Endocrine-related cancer.
[18] R. Medema,et al. p53 Prohibits Propagation of Chromosome Segregation Errors that Produce Structural Aneuploidies. , 2017, Cell reports.
[19] Angelika Amon,et al. Chromosome Mis-segregation Generates Cell-Cycle-Arrested Cells with Complex Karyotypes that Are Eliminated by the Immune System. , 2017, Developmental cell.
[20] D. Beebe,et al. High rates of chromosome missegregation suppress tumor progression but do not inhibit tumor initiation , 2016, Molecular biology of the cell.
[21] Jan O. Korbel,et al. Negative Selection and Chromosome Instability Induced by Mad2 Overexpression Delay Breast Cancer but Facilitate Oncogene-Independent Outgrowth , 2016, Cell reports.
[22] D. Compton,et al. Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells. , 2016, Cancer discovery.
[23] Shiv D. Kale,et al. Selective advantage of trisomic human cells cultured in non-standard conditions , 2016, Scientific Reports.
[24] Ashley M. Laughney,et al. Dynamics of Tumor Heterogeneity Derived from Clonal Karyotypic Evolution. , 2015, Cell Reports.
[25] R. Medema,et al. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] K. Polyak,et al. Oncogene-like induction of cellular invasion from centrosome amplification , 2014, Nature.
[27] J. O’Shaughnessy,et al. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer , 2014, Breast Cancer Research and Treatment.
[28] Mark E. Burkard,et al. Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles , 2014, Science Translational Medicine.
[29] Eiman Mukhtar,et al. Targeting Microtubules by Natural Agents for Cancer Therapy , 2014, Molecular Cancer Therapeutics.
[30] A. Amon,et al. Aneuploidy: implications for protein homeostasis and disease , 2014, Disease Models & Mechanisms.
[31] Lauren M. Zasadil,et al. Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors , 2013, Proceedings of the National Academy of Sciences.
[32] P. Albers,et al. Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer , 2013, Investigational New Drugs.
[33] Jordan Ma,et al. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. , 2012 .
[34] T. Campbell,et al. Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis. , 2012, Cancer treatment reviews.
[35] Weimin Bi,et al. Aneuploidy as a mechanism for stress-induced liver adaptation. , 2012, The Journal of clinical investigation.
[36] J. Baselga,et al. Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.
[37] R. Schmid,et al. A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network , 2012, British Journal of Cancer.
[38] M. Minden,et al. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia , 2012, Investigational New Drugs.
[39] A. Tan,et al. A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors , 2012, Investigational New Drugs.
[40] E. Heath,et al. First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer , 2012, Cancer Chemotherapy and Pharmacology.
[41] A. Fojo,et al. Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale , 2012, Clinical Cancer Research.
[42] T. Fojo,et al. Mitosis is not a key target of microtubule agents in patient tumors , 2011, Nature Reviews Clinical Oncology.
[43] Christopher D. Cox,et al. Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs. , 2010, Anti-cancer agents in medicinal chemistry.
[44] D. Compton,et al. CLASP1, astrin and Kif2b form a molecular switch that regulates kinetochore‐microtubule dynamics to promote mitotic progression and fidelity , 2010, The EMBO journal.
[45] K. Pollok,et al. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD‐2076, against multiple myeloma , 2010, British journal of haematology.
[46] H. Kovar. AURKA inhibitors: Right in time , 2010, Pediatric blood & cancer.
[47] Neysa Nevins,et al. Antitumor activity of an allosteric inhibitor of centromere-associated protein-E , 2010, Proceedings of the National Academy of Sciences.
[48] Leslie Wilson,et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. , 2010, Biochemistry.
[49] J. D. Elliott,et al. Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295. , 2010, ACS medicinal chemistry letters.
[50] D. Baker,et al. Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity. , 2009, Cancer cell.
[51] Jeffrey Ecsedy,et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. , 2009, Blood.
[52] R. Medema,et al. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells , 2009, Proceedings of the National Academy of Sciences.
[53] B. Tunquist,et al. ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models. , 2009, Anticancer Research.
[54] J. Berman,et al. Acquisition of Aneuploidy Provides Increased Fitness during the Evolution of Antifungal Drug Resistance , 2009, PLoS genetics.
[55] David A. Smith,et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] P. Schöffski. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. , 2009, The oncologist.
[57] M. Dimopoulos,et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer , 2009, Breast Cancer Research and Treatment.
[58] Samuel F. Bakhoum,et al. Genome stability is ensured by temporal control of kinetochore-microtubule dynamics , 2008, Nature Cell Biology.
[59] Stephen S. Taylor,et al. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. , 2008, Cancer cell.
[60] D. Baker,et al. Bub1 mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis , 2007, The Journal of cell biology.
[61] Maitreya J. Dunham,et al. Effects of Aneuploidy on Cellular Physiology and Cell Division in Haploid Yeast , 2007, Science.
[62] J. Sparano,et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] E. Perez,et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] D. Compton,et al. The kinesin-13 proteins Kif2a, Kif2b, and Kif2c/MCAK have distinct roles during mitosis in human cells. , 2007, Molecular biology of the cell.
[65] Péter Lénárt,et al. BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.
[66] J. Peters,et al. The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1 , 2007, Current Biology.
[67] D. Compton,et al. Mechanisms of Spindle-Pole Organization Are Influenced by Kinetochore Activity in Mammalian Cells , 2007, Current Biology.
[68] B. Overmoyer,et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] Marina Bibikova,et al. Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. , 2005, Molecular biology of the cell.
[70] D. Green,et al. Apoptotic Pathways: Ten Minutes to Dead , 2005, Cell.
[71] Helder Maiato,et al. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. , 2004, Developmental cell.
[72] G. Chin,et al. Gene silencing of CENP-E by small interfering RNA in HeLa cells leads to missegregation of chromosomes after a mitotic delay. , 2004, Molecular biology of the cell.
[73] Geert J P L Kops,et al. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[74] M. Jordan,et al. Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.
[75] S. Horwitz,et al. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. , 2002, Cancer research.
[76] W. Gerald,et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells , 2001, Nature.
[77] D. Richel,et al. Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy , 1999 .
[78] Bas van Steensel,et al. TRF2 Protects Human Telomeres from End-to-End Fusions , 1998, Cell.
[79] B. Schaar,et al. CENP-E Function at Kinetochores Is Essential for Chromosome Alignment , 1997, The Journal of cell biology.
[80] P Wadsworth,et al. Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro. , 1997, Molecular biology of the cell.
[81] K. Kinzler,et al. Genetic instability in colorectal cancers , 1997, Nature.
[82] Kevin C. Chu,et al. Differential Effects of Vinblastine on Polymerization and Dynamics at Opposite Microtubule Ends* , 1996, The Journal of Biological Chemistry.
[83] E. Eisenhauer,et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] P. Wadsworth,et al. Vinblastine suppresses dynamics of individual microtubules in living interphase cells. , 1995, Molecular biology of the cell.
[85] E. Lazarides,et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. , 1995, Cancer research.
[86] W. B. Derry,et al. Substoichiometric binding of taxol suppresses microtubule dynamics. , 1995, Biochemistry.
[87] J. Garcia-conde,et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[88] M. Jordan,et al. Mechanism of inhibition of cell proliferation by Vinca alkaloids. , 1991, Cancer research.
[89] S. N. Timasheff,et al. Colchicine analogues that bind reversibly to tubulin define microtubular requirements for newly synthesized protein secretion in rat lacrimal gland. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[90] J Parness,et al. Taxol binds to polymerized tubulin in vitro , 1981, The Journal of cell biology.
[91] J. Lee,et al. Effects of nocodazole on structures of calf brain tubulin. , 1980, Biochemistry.
[92] P. Schiff,et al. Taxol stabilizes microtubules in mouse fibroblast cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[93] B. Bhattacharyya,et al. Colcemid and colchicine binding to tubulin , 1979, FEBS letters.
[94] P. Schiff,et al. Promotion of microtubule assembly in vitro by taxol , 1979, Nature.
[95] F. Frankel. Organization and energy-dependent growth of microtubules in cells. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[96] M. De Brabander,et al. Interaction of oncodazole (R 17934), a new antitumoral drug, with rat brain tubulin. , 1976, Biochemical and biophysical research communications.
[97] S. Malawista,et al. Microtubule Crystals: A New Biophysical Phenomenon induced by Vinca Alkaloids , 1968, Nature.
[98] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[99] J. Ward,et al. Heterozygous deletion of mitotic arrest-deficient protein 1 (MAD1) increases the incidence of tumors in mice. , 2007, Cancer research.
[100] Cristina Montagna,et al. Aneuploidy acts both oncogenically and as a tumor suppressor. , 2007, Cancer cell.
[101] M. Jordan,et al. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. , 2002, Current medicinal chemistry. Anti-cancer agents.
[102] D. Richel,et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] P. Giannakakou,et al. Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol®)* , 1997, The Journal of Biological Chemistry.
[104] B. Kopnin,et al. Comparison of mitostatic effect, cell uptake and tubulin-binding activity on colchicine and colcemid. , 1981, Biochimica et biophysica acta.
[105] D. Purich,et al. Taxol induces microtubule assembly at low temperature. , 1981, Cell motility.
[106] R. Johnson,et al. Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. , 1978, Cancer treatment reports.
[107] M. Fernández-Gómez,et al. Colchicine Effect on the Mitotic Spindle: Estimate of Multipolar Anaphase Production , 1974 .